DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document Mar 26, 2026 05:19PM
DBV Technologies Reports Full Year 2025 Financial Results and Business Update Mar 26, 2026 05:06PM
DBV Technologies completes last patient visit in peanut patch trial Nov 11, 2025 11:50PM
DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years Nov 11, 2025 11:50PM
DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report Jul 29, 2025 04:17PM


Jul 29, 2025 04:08PM DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results
Mar 24, 2025 02:30AM DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, &a
May 31, 2024 09:51AM DBV Technologies Announces Plan to Implement ADS Ratio Change
Apr 25, 2024 04:30PM Combined General Meeting of May 16, 2024
Mar 8, 2024 09:33AM DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document
May 14, 2018 08:32AM DBV Technologies Partners with FARE to Help Raise Awareness of Food Allergies in Support of the 21st Anniversary of Food Allergy Awareness Week
Nov 20, 2014 01:43AM DBV Technologies Initiates Phase I/II Clinical Trial with Viaskin Milk for the Treatment of Children with Cow's Milk Allergy